and a 36-month beta value of 1.21. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 10 as “hold,” and 3 as “sell.”
The average price predicted for Teva Pharmaceutical Industries Limited (TEVA) by analysts is $10.15, which is $1.65 above the current market price. The public float for TEVA is 1.10B, and at present, short sellers hold a 2.32% of that float. On March 17, 2023, the average trading volume of TEVA was 8.78M shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
TEVA) stock’s latest price update
Teva Pharmaceutical Industries Limited (NYSE: TEVA)’s stock price has decreased by -1.96 compared to its previous closing price of 8.67. However, the company has experienced a -8.80% decline in its stock price over the last five trading sessions. The Wall Street Journal reported on 11/21/22 that Teva Pharmaceutical Names Richard Francis as CEO
TEVA’s Market Performance
TEVA’s stock has fallen by -8.80% in the past week, with a monthly drop of -17.07% and a quarterly drop of -6.70%. The volatility ratio for the week is 2.78% while the volatility levels for the last 30 days are 2.36% for Teva Pharmaceutical Industries Limited The simple moving average for the last 20 days is -12.43% for TEVA stock, with a simple moving average of -6.39% for the last 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Jefferies repeating the rating for TEVA by listing it as a “Hold.” The predicted price for TEVA in the upcoming period, according to Jefferies is $12 based on the research report published on January 19th of the current year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $10, previously predicting the price at $11. The rating they have provided for TEVA stocks is “Underweight” according to the report published on November 14th, 2022.
TEVA Trading at -16.53% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.73% of loss for the given period.
Volatility was left at 2.36%, however, over the last 30 days, the volatility rate increased by 2.78%, as shares sank -17.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.81% lower at present.
During the last 5 trading sessions, TEVA fell by -8.80%, which changed the moving average for the period of 200-days by -5.97% in comparison to the 20-day moving average, which settled at $9.62. In addition, Teva Pharmaceutical Industries Limited saw -6.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Dethlefs Sven, who sale 58,066 shares at the price of $9.43 back on Mar 07. After this action, Dethlefs Sven now owns 165,381 shares of Teva Pharmaceutical Industries Limited, valued at $547,440 using the latest closing price.
Daniell Richard, the Exec. VP, European Commercial of Teva Pharmaceutical Industries Limited, sale 54,007 shares at $9.43 during a trade that took place back on Mar 07, which means that Daniell Richard is holding 69,770 shares at $509,173 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- +17.96 for the present operating margin
- +46.68 for the gross margin
The net margin for Teva Pharmaceutical Industries Limited stands at -15.78. The total capital return value is set at 8.36, while invested capital returns managed to touch -8.02. Equity return is now at value -26.80, with -5.20 for asset returns.
Based on Teva Pharmaceutical Industries Limited (TEVA), the company’s capital structure generated 274.21 points at debt to equity in total, while total debt to capital is 73.28. Total debt to assets is 49.21, with long-term debt to equity ratio resting at 246.32. Finally, the long-term debt to capital ratio is 65.83.
When we switch over and look at the enterprise to sales, we see a ratio of 2.02, with the company’s debt to enterprise value settled at 0.72. The receivables turnover for the company is 3.69 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
To sum up, Teva Pharmaceutical Industries Limited (TEVA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “sell” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
